Proteinase 3-ANCA vasculitis versus myeloperoxidase- ANCA vasculitis

182Citations
Citations of this article
193Readers
Mendeley users who have this article in their library.

Abstract

In patients with GN or vasculitis, ANCAs are directed against proteinase 3 (PR3) or myeloperoxidase (MPO). The differences between PR3-ANCA-associated vasculitis (AAV) andMPO-AAV described in the past have been supplemented during the last decade. In this review, we discuss the differences between these two small-vessel vasculitides, focusing especially on possible etiologic and pathophysiologic differences. PR3-AAV ismore common in northern parts of the world, whereasMPO-AAV is more common in southern regions of Europe, Asia, and the Pacific, with the exception of New Zealand and Australia. A genetic contribution has been extensively studied, and there is a high prevalence of the HLA-DPB1∗04:01 allele in patients with PR3-AAV as opposed to patients with MPO-AAV and/or healthy controls. Histologically, MPO-AAV and PR3-AAV are similar but show qualitative differences when analyzed carefully. Clinically, both serotypes are difficult to distinguish, but quantitative differences are present. More organs are affected in PR3-AAV, whereas renal limited vasculitis occurs more often in patients with MPO-AAV. For future clinical trials, we advocate classifying patients by ANCA serotype as opposed to the traditional disease type classification.

Cite

CITATION STYLE

APA

Hilhorst, M., Van Paassen, P., & Tervaert, J. W. C. (2015, October 1). Proteinase 3-ANCA vasculitis versus myeloperoxidase- ANCA vasculitis. Journal of the American Society of Nephrology. American Society of Nephrology. https://doi.org/10.1681/ASN.2014090903

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free